Pramipexole, the active ingredient in the Parkinson’s disease therapy Mirapex, appears to overactivate a brain region known as…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Parkin, a protein linked to Parkinson’s disease that’s lost in certain types of cancer, triggers the release of signaling…
Ten consecutive weeks of either high-intensity interval training or continuous training, which is moderate in intensity, effectively eased disease…
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce…
Note: This story was updated Sept. 16, 2024, to correct that A-dopamine is a form of dopamine. Levodopa, a…
Rune Labs has launched StrivePD-AI, a new feature in its StrivePD app that uses generative artificial intelligence (GenAI) to…
The American Parkinson Disease Association (APDA) has awarded a total of $2.6 million for the 2024-2025 funding year, to…
The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay…
The brain weakens unused neural connections in the striatum, a region involved in motor control and decision-making, through a nitric…
Having acute kidney injury increases the risk of developing dementia, including Parkinson’s disease with dementia, according to a study…